Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial
Couplée à l'essai "Prostate Cancer Prevention Trial", cette étude prospective cas-témoins (614 cas et 616 témoins) évalue l'association entre une séropositivité au cytomégalovirus et le risque de cancer de la prostate
Purpose To investigate serologic evidence of infection by cytomegalovirus (CMV), a herpesvirus with known oncogenic potential that has been detected in malignant prostate tissue, in relation to prostate cancer (PCa) risk in a large case–control study nested in the Prostate Cancer Prevention Trial (PCPT). Methods Cases were men with a confirmed diagnosis of PCa after visit 2 ( n = 614), and controls were men not diagnosed with PCa during the trial who also had a negative end-of-study biopsy ( n = 616). Controls were frequency-matched to cases by age, treatment arm, and family history of PCa. Sera from visit 2 were tested for CMV IgG antibodies. Results No association was observed between CMV serostatus and PCa risk (adjusted CMV seroprevalence = 67.9 % for cases and 65.2 % for controls, odds ratio = 1.13, 95 % CI 0.89–1.45). Conclusions Considering our null findings in the context of the full CMV literature, CMV infection, as measured by serostatus, does not appear to increase PCa risk.